相关实验视频
Updated: Feb 28, 2026

14:57
Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
10.1K
用小分子稳定剂rezatapoptopt针对p53癌症突变Y220C,Y220N和Y220S进行向
Danai Mavridi1,2, Julianne S Funk3, Dimitrios-Ilias Balourdas1,2
1Institute of Pharmaceutical Chemistry, Goethe University, Max-von-Laue-Str. 9, 60438, Frankfurt am Main, Germany.
Cell death & disease
|February 26, 2026
概括
雷扎塔普托普特药物在重新激活p53癌症突变Y220C和Y220S方面表现有前途,恢复蛋白质稳定性和抗癌作用. 然而,对Y220N突变的疗效仍然有限,这给开发泛突变疗法带来了挑战.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 在癌症中,p53瘤抑制蛋白经常发生突变,Y220C突变造成了新疗法准的破坏稳定的裂.
- 突变Y220N和Y220S不那么常见,但比Y220C更具破坏性,共享类似的表面裂.
研究的目的:
- 为了研究突变的p53活性剂rezatapopt对Y220N和Y220Sp53突变的疗效.
- 阐明rezatapopt与这些p53突变物相互作用的结合方式和结构基础.
主要方法:
- 生物物理测试以确定结合亲和力和蛋白质稳定性.
- 高分辨率的晶体结构确定与Y220C,Y220N和Y220S p53突变体结合的rezatapopt.
- 基于细胞的测试测量p53信号,增殖和亡.
主要成果:
- 雷萨塔托普特结合了具有纳米分子亲和力的Y220N和Y220S突变体,完全稳定了Y220S到与野生类型类似的水平.
- 结构分析揭示了所有三种突变体的保留结合模式,其中关键的相互作用涉及替代剂.
- 在测试度下,rezataptopt在Y220C和Y220S细胞中重新激活了p53信号,并表现出抗增殖作用,但在Y220N细胞中没有.
- 通过rezatapopt部分稳定Y220N并没有转化为细胞疗效,这是由结构性发现解释的.
结论:
- 雷扎塔普托普显示出治疗具有Y220C和Y220S p53突变的癌症的潜力.
- 开发一种针对所有Y220C/N/S突变物有效的单一药物,由于细胞反应差异,这将带来重大挑战.
- 需要进一步的研究来设计泛-Y220C/N/S反应器,以获得更广泛的患者益处.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Abnormal Proliferation
5.3K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.3K
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Negative Regulator Molecules
38.7K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.7K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

